Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients, and to Evaluate the Safety and Preliminary Efficacy in Advanced Esophagus Canver and Squamous Cell Carcinoma of the Esophageal Junction Patients

Trial Profile

A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients, and to Evaluate the Safety and Preliminary Efficacy in Advanced Esophagus Canver and Squamous Cell Carcinoma of the Esophageal Junction Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2018

At a glance

  • Drugs HH-CYH33 (Primary)
  • Indications Oesophageal cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Haihe Biopharma; ShangHai HaiHe Pharmaceutical
  • Most Recent Events

    • 08 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top